CT News and Research

RSS

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

State highlights: Mo.'s declining Medicaid caseload; N.C. budget would cut Medicaid rolls; Calif. paid sick leave

Missouri is seeing a bigger decline in its Medicaid rolls than nearly any other state, a ranking that the Nixon administration attributes to an improving economy and critics blame on application snafus.

31 May 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

3D scans uncover the truth about Richard III’s spinal condition

Researchers, led by Professor Bruno Morgan at the University of Leicester, have finally been able to describe the precise nature of King Richard III’s spinal condition. He had scoliosis, causing his spine to curve to one side. He would have had a small but noticeable defect, which is unlikely to have interfered with his ability to exercise.

30 May 2014

Tai Chi intervention offers anti-aging benefits, says study

Tai Chi, a traditional Chinese martial art and sport, has been found to be beneficial in raising the numbers of an important type of cell when three groups of young people were tested to discover the benefits of Tai Chi, brisk walking or no exercise.

29 May 2014

Georgia disputes reports of big Medicaid enrollment jump

According to the state's Department of Community Health, the increase in enrollment was about 37,000, significantly lower than the nearly 99,000 estimated by a consulting group earlier this year.

29 May 2014

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.

28 May 2014

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.

28 May 2014

Findings explain why women with bladder cancer are often diagnosed at later stage than men

Women with blood in their urine (hematuria) were less than half as likely as men with the same issue to be referred to a urologist for further tests, according to a new Vanderbilt University study.

28 May 2014

Chest CT helps identify individuals at risk for future heart attacks

Incidental chest computed tomography (CT) findings can help identify individuals at risk for future heart attacks and other cardiovascular events, according to a new study published online in the journal Radiology.

27 May 2014

BIOTRONIK ProMRI ICD trial expansion achieves FDA approval

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration (FDA) has approved a significant expansion of its ongoing ProMRI® trial.

23 May 2014

NCCN receives $2M grant to evaluate effectiveness of volasertib in treatment of hematologic malignancies

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc.

23 May 2014

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).

22 May 2014

Nevada to use federal exchange for next open enrollment

The board of Nevada's online insurance exchange voted Tuesday to scrap its contract with Xerox, which built the exchange that has been marked by problems.

22 May 2014

State highlights: Calif. bill on keeping small biz health plans; Colo. rating area plan approved

A selection of health policy stories from California, Colorado, Connecticut, Washington state and Massachusetts.

21 May 2014

First Edition: May 20, 2014

Today's headlines include the latest reports on various states' challenges related to expanding the Medicaid program.

20 May 2014

Barnes-Jewish Hospital first to use VISIUS iMRI for over 1,000 procedures

IMRIS Inc. ("IMRIS" or the "Company") today announced that Barnes-Jewish Hospital in St. Louis is the first U.S. hospital to use VISIUS® iMRI for more than 1,000 procedures.

20 May 2014

Highlights: Nurse practitioners fight for autonomy in Texas; Ohio physician assistant prescriptions; drug options in Colo.

A selection of health policy stories from Texas, Ohio, Colorado, North Carolina, Massachusetts, Alabama, Connecticut and Kansas.

20 May 2014

Dassault Systèmes launches world's first 3D simulation model of human heart

Dassault Systèmes (Paris:DSY)(Euronext Paris: #13065, DSY.PA), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, today unveiled the world's first 3D realistic simulation model of a whole human heart.

20 May 2014

New technique can predict which stroke victims will benefit from clot-busting drugs

Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.

20 May 2014

CT News and Research

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

State highlights: Mo.'s declining Medicaid caseload; N.C. budget would cut Medicaid rolls; Calif. paid sick leave

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

3D scans uncover the truth about Richard III’s spinal condition

Tai Chi intervention offers anti-aging benefits, says study

Georgia disputes reports of big Medicaid enrollment jump

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

Findings explain why women with bladder cancer are often diagnosed at later stage than men

Chest CT helps identify individuals at risk for future heart attacks

BIOTRONIK ProMRI ICD trial expansion achieves FDA approval

NCCN receives $2M grant to evaluate effectiveness of volasertib in treatment of hematologic malignancies

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Nevada to use federal exchange for next open enrollment

State highlights: Calif. bill on keeping small biz health plans; Colo. rating area plan approved

First Edition: May 20, 2014

Barnes-Jewish Hospital first to use VISIUS iMRI for over 1,000 procedures

Highlights: Nurse practitioners fight for autonomy in Texas; Ohio physician assistant prescriptions; drug options in Colo.

Dassault Systèmes launches world's first 3D simulation model of human heart

New technique can predict which stroke victims will benefit from clot-busting drugs

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News